Skip to main content

Radiation Dose Management Market growing at a CAGR of10.96% between 2021-2030

 Since the discovery of X-ray and ionizing radiations in the 1890s, the probable prospects of radiation usage for diagnosis were explored and studied. Further innovations in the field of medical devices paved the way for better application of radiation. The radiology sector has rapidly evolved in recent years with the emergence of advanced imaging technologies, capturing and interpreting the diseases, which can be later explored for disease monitoring and treatment.

However, the rising usage of radiation-derived technologies has led to an upsurge of consequences that pose a threat to human lives. This is one of the significant challenges concerning overexposures and has pressured the regulatory bodies to formulate laws with respect to dose monitorization. Thus, systematic and constant monitoring of radiation dose is vital to increase the overall quality of the radiological services to patients. Additionally, dose monitoring rises awareness among hospital staff, radiographers, radiologists, and medical physicists with improved dosimetry statistics.

The global radiation dose management market is driven by increasing installed bases of radiology and number of scans, growing geriatric population, and the increasing prevalence of chronic and lifestyle-associated diseases, such as cancer, respiratory disease, and cardiovascular diseases.

However, many hospitals have not historically used radiation dose management software as a quality benchmarking tool. With the rising prevalence of cancer cases or chronic diseases, coupled with the implementation of strict guidelines that mandate to regulate the minimal dose exposed through a product, led to the adoption of radiation management tools. This has enhanced the IT integration and interoperability of both patient and staff dose data to accurately track, capture, and measure information to assess quality in the long term.

Rising demand for radiation dose management awareness, increasing geriatric population, and increasing install base of radiology products are some of the factors promoting the growth of radiation dose management software in this region. The radiation dose management market is expected to reach $567.3 million by 2030, growing at a CAGR of10.96% during the forecast period 2021-2030. Major growth factors driving the market include the increasing incidence of lifestyle-related diseases and the rising demand for radiation-based diagnostic devices.

The presence of limited companies in the radiation dose management industry and the increasing regulations for radiation dose have increased the competition in the global market. Increasing awareness regarding radiation over exposure and its side-effects have increased the demand for radiation dose management software.

The radiation dose management market is gradually growing over time, compelling several companies to come up with collaborative strategies to sustain the intensely competitive market. Companies with identical goals pool in resources and sign agreements to assist each other in achieving those goals. The software platform permits medical professionals to manage, examine, and optimize dose delivered to patients during interventional procedures, medical imaging examination, and image-guided surgery.

The radiation dose management market is witnessing a significant increase in the market size due to the ongoing COVID-19 pandemic. The overall market was estimated to be $231.1 million in FY2019, and it is expected to grow at a CAGR of 10.96% during the forecast period, 2021-2030. Presently, more than 21 companies are operating in this market, including already existing and emerging medical device companies.

Request a Sample - https://bisresearch.com/requestsample?id=1053&type=download







Comments

Popular posts from this blog

Microbiome Therapeutics Market Growth, Segmentation, Opportunity and Forecast to 2032

  Global microbiome therapeutics market is expected to grow further in the coming years due to the continuous increase in awareness and need for better and safer treatment alternatives and the dominance of gastrointestinal (GI) and infectious diseases segment can be attributed to the existing dominance of microbiome therapeutics available for a variety of indications ranging from diarrhea and gut dysbiosis to skin disorders, cancer indications among others. The global microbiome therapeutics market which accounted for $306.3 million in 2021 is expected to reach $3,204 million by 2032, reporting a CAGR of 24.95% during the forecast period 2022-2032. The existing   microbiome therapeutics market    is favored by multiple factors, including the rising geriatric populations coupled with the increasing adoption of inorganic growth strategies by key players in the market. Impact of COVID-19 There were numerous consequences due to the COVID-19 pandemic, especially...

Ligase Market Opportunities, Strategies, Share, Segmentation, In-depth Analysis 2032

  The global ligase market is progressing rapidly with a significant increase in the research and development activities pertaining to a wide range of ligase product for disease detection, accentuating their criticality in healthcare. Ligase enzyme has a critical role in the molecular diagnostics approach, as it ensures the safe and effective application of targeted therapeutics. Most of the players in the global ligase market offer products encompassing the ligation kits and enzymes. The global  ligase market  is projected to reach $651.4 million by 2032 from $371.2 million in 2021, at a CAGR of 5.29% during the forecast period 2022-2032. The growth in the global ligase market is expected to be driven by factors such as the increasing prevalence of infectious and genetic diseases on a global level, rising awareness of enzyme based diagnostic testing and significant number of funding for executing research and development.   Impact Several techniques are employed in ...

PD-1/PDL-1 Inhibitor Market Growth Prospects, Emerging Trends and Forecast to 2032

  PD-1/PDL-1 inhibitors are immune-therapeutic agents used in the treatment of various cancer indications, mostly in the advanced stages. PD-1/PDL-1 inhibitors are monoclonal antibodies majorly of IgG1 and IgG4 types to be administered to patients via injection The current market already has seven approved products in the U.S. and a large number of research activities are currently undergoing in this segment generating interest of commercial as well as academic research institutions. In the current period of precision medicine and providing targeted treatment, identification of target patient has become very important as well as complicated. With the emergence of diagnostic test identifying predictive biomarkers, the selection and administration of targeted treatment has become comparativlely conveninent and efficient. PD-1/PDL-1 inhibitors market   are majorly indicated for the treatment of advanced cases of different cancer indications. The PD-1/PDL-1 inibitor treatment has ...